{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T20:35:36Z","timestamp":1648672536371},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bulcan.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T22:23:04Z","timestamp":1514413384000},"page":"81-98","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Le lymphome de Hodgkin\u00a0: strat\u00e9gies th\u00e9rapeutiques actuelles et futures"],"prefix":"10.1016","volume":"105","author":[{"given":"Anthony","family":"Turpin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Mazeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Terroir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Boros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Bonnetier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Coman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Danu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ghez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Pilorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Arfi-Rouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Carde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Ferm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lazarovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bulcan.2017.11.008_bib0495","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008\u00a0WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0500","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/095952873201700106","article-title":"null: on some morbid appearances of the absorbent glands and spleen","volume":"17","author":"Hodgkin","year":"1832","journal-title":"Med Chir Trans"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0980","series-title":"Estimation nationale de l\u2019incidence des cancers en France entre 1980 et 2012. Partie 2 \u2013 H\u00e9mopathies malignes","first-page":"88","author":"Monnereau","year":"2013"},{"issue":"7","key":"10.1016\/j.bulcan.2017.11.008_bib0510","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM199502163320701","article-title":"Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease","volume":"332","author":"Mack","year":"1995","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2017.11.008_bib0515","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/cncr.20189","article-title":"Familial aggregation of Hodgkin lymphoma and related tumors","volume":"100","author":"Goldin","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2017.11.008_bib0520","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/annonc\/mdt218","article-title":"Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph)","volume":"24","author":"Kamper-J\u00f8rgensen","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0525","first-page":"358","article-title":"Malignancies associated with epstein\u2013barr virus: pathobiology, clinical features, and evolving treatments","volume":"12","author":"Neparidze","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0530","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2015.06.002","article-title":"Microenvironment and HIV-related lymphomagenesis","volume":"34","author":"Pantanowitz","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0535","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood","volume":"18","author":"van Leeuwen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2017.11.008_bib0540","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1200\/JCO.2016.67.4358","article-title":"Reply to D. Vordermark and T. Pelz and R. Mazzola et al","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2017.11.008_bib0545","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0550","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0555","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2017.11.008_bib0560","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0565","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijrobp.2015.02.012","article-title":"Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis","volume":"92","author":"Gerber","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.bulcan.2017.11.008_bib0570","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1684\/bdc.2014.2021","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management","volume":"101","author":"Gorde-Grosjean","year":"2014","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0575","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/10428194.2011.608455","article-title":"The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management","volume":"53","author":"Hawkes","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.bulcan.2017.11.008_bib0580","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1634\/theoncologist.2009-0099","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma","volume":"14","author":"Lee","year":"2009","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bulcan.2017.11.008_bib0585","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.bulcan.2017.11.008_bib0590","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"issue":"23","key":"10.1016\/j.bulcan.2017.11.008_bib0595","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed\u2013Sternberg cells picked from histological sections show clonal immuno-globulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0600","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed\u2013Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0605","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0610","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0615","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","article-title":"Coexpression of BMI-1\u00a0and EZH2\u00a0polycomb group genes in Reed\u2013Sternberg cells of Hodgkin's disease","volume":"157","author":"Raaphorst","year":"2000","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.11.008_bib0620","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0625","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/asheducation-2014.1.144","article-title":"The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling","volume":"2014","author":"Scott","year":"2014","journal-title":"Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program"},{"issue":"39","key":"10.1016\/j.bulcan.2017.11.008_bib0630","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8T cells by alphaPD-L1\u00a0blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.bulcan.2017.11.008_bib0635","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1\u00a0and PD-L2\u00a0genetic alterations define classical Hodgkin Lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0640","first-page":"1","article-title":"Lymphome de Hodgkin de l\u2019adulte","volume":"6","author":"Ferm\u00e9","year":"2011"},{"issue":"9844","key":"10.1016\/j.bulcan.2017.11.008_bib0645","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0650","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0","article-title":"Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis","volume":"71","author":"Mauch","year":"1993","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0655","first-page":"1225","article-title":"Evidence for an orderly progression in the spread of Hodgkin's disease","volume":"26","author":"Rosenberg","year":"1966","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0660","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-8140(97)00208-9","article-title":"Contiguous pattern spreading in patients with Hodgkin's disease","volume":"47","author":"Roth","year":"1998","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.11.008_bib0665","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3109\/10428194.2011.584993","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network","volume":"52","author":"Farrell","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0670","unstructured":"Haute Autorit\u00e9 de Sant\u00e9\/Service des maladies chroniques et dispositifs d\u2019accompagnement des malades INCa\/D\u00e9partement diffusion des bonnes pratiques et information des malades. Recommandations HAS\/INCA: - Actualisation Septembre 2014."},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0675","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clml.2014.01.006","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment","volume":"14","author":"Goel","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.bulcan.2017.11.008_bib0680","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.bulcan.2017.11.008_bib0685","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2017.11.008_bib0690","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9828","key":"10.1016\/j.bulcan.2017.11.008_bib0695","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15\u00a0trial): a randomised, open-label, phase 3\u00a0non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bulcan.2017.11.008_bib0700","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMc0906731","article-title":"Long-term follow-up of survival in Hodgkin's Lymphoma","volume":"361","author":"Canellos","year":"2009","journal-title":"N Engl J Med"},{"issue":"66","key":"10.1016\/j.bulcan.2017.11.008_bib0705","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0609.2005.00467.x","article-title":"The EORTC strategy in the treatment of Hodgkin's lymphoma","volume":"75","author":"Eghbali","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0710","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol Off"},{"issue":"19","key":"10.1016\/j.bulcan.2017.11.008_bib0715","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2017.11.008_bib0720","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma","author":"Herbst","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.bulcan.2017.11.008_bib0725","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.10.018","article-title":"Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease","volume":"78","author":"Shahidi","year":"2006","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0735","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2017.11.008_bib0740","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0745","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.bulcan.2017.11.008_bib0750","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","author":"Hutchings","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.11.008_bib0755","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/2040620715625615","article-title":"The evolving role of response-adapted PET imaging in Hodgkin lymphoma","volume":"7","author":"Coyle","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"10.1016\/j.bulcan.2017.11.008_bib0760","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2017.11.008_bib0985","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2017.11.008_bib0770","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0775","first-page":"CD010533","article-title":"Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma","volume":"1","author":"Sickinger","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.bulcan.2017.11.008_bib0780","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2017.11.008_bib0785","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.bulcan.2017.11.008_bib0790","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10\u00a0years of follow-up of the GHSG HD9\u00a0study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2017.11.008_bib0795","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000\u00a0Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.11.008_bib0800","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bulcan.2017.11.008_bib0805","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score\u22653, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012\u00a0intergroup trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0810","article-title":"Randomized phase III study comparing an early PET driven treatment De-Escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin Lymphoma: interim analysis of the AHL2011\u00a0Lysa Study","author":"Casasnovas","year":"2015","journal-title":"Abstract"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0815","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58\u00a0children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-K\u00f6rholz","year":"2007","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.bulcan.2017.11.008_bib0820","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2\u00a0study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"issue":"8852","key":"10.1016\/j.bulcan.2017.11.008_bib0825","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1016\/j.bulcan.2017.11.008_bib0830","doi-asserted-by":"crossref","first-page":"2065-2071","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bulcan.2017.11.008_bib0835","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0840","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0845","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/annonc\/mdj995","article-title":"Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma","volume":"17","author":"Hertzberg","year":"2006","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2017.11.008_bib0850","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1023\/A:1008343823292","article-title":"Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM\/GELA Study Group","volume":"10","author":"Brice","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2017.11.008_bib0855","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.bulcan.2017.11.008_bib0860","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0865","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0870","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","article-title":"The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease","volume":"6","author":"Ferm\u00e9","year":"1995","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0875","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2015.136408","article-title":"Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96\u00a0trial by the LYSA\/SFGM-TC study group","volume":"101","author":"Sibon","year":"2016","journal-title":"Haematologica"},{"issue":"9980","key":"10.1016\/j.bulcan.2017.11.008_bib0880","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bulcan.2017.11.008_bib0885","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0890","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.11.008_bib0895","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2017.11.008_bib0900","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2017.11.008_bib0905","doi-asserted-by":"crossref","first-page":"1628-1635","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2017.11.008_bib0910","first-page":"2183-2189","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"Am J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2017.11.008_bib0915","first-page":"2197-2203","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2017.11.008_bib0920","doi-asserted-by":"crossref","first-page":"1222-1228","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2\u00a0trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2017.11.008_bib0925","doi-asserted-by":"crossref","first-page":"5119-5125","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2\u00a0multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2017.11.008_bib0930","doi-asserted-by":"crossref","first-page":"311-319","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1\u00a0blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.bulcan.2017.11.008_bib0935","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1\u00a0blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0940","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V126.23.586.586","volume":"126","author":"Sawas","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2017.11.008_bib0945","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.3324\/haematol.2015.124784","article-title":"Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma","volume":"100","author":"Michallet","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2017.11.008_bib0950","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"A safety and activity of Brentuximab Vedotin (Bv) plus Ifosfamide, Carboplatin, and Etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin Lymphoma (cHL): initial results of a phase I\/II trial","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0955","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1\u00a0ligand interaction contributes to immuno-suppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2017.11.008_bib0960","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1\u00a0amplification, increased PD-1\u00a0ligand expression, and further induction via JAK2\u00a0in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2017.11.008_bib0965","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1\u00a0activity and EBV infection induce PD-L1\u00a0in Hodgkin lymphomas and post-transplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.bulcan.2017.11.008_bib0990","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2017.11.008_bib0975","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immuno-modulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2017.11.008_bib0490","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bulcan.2016.11.005","article-title":"New therapy outlooks in Hodgkin lymphoma","volume":"104","author":"Rossi","year":"2017","journal-title":"Bull Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T23:49:59Z","timestamp":1603583399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117303764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0007455117303764"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le lymphome de Hodgkin\u00a0: strat\u00e9gies th\u00e9rapeutiques actuelles et futures","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}